How would you approach a patient with metastatic ER+/Her2+ who has progressed on trastuzumab/pertuzumab + tamoxifen after being in remission for 4yrs?

Topics: Breast Cancer • Medical Oncology • Her2+ • HR+

Answer from: Medical Oncologist at Academic Institution

There are several options for this patient, including 1) continuing Herceptin/Pertuzumab and change tamoxifen to a different hormonal therapy agent, 2) continuing Herceptin/Pertuzumab and switching hormonal therapy to a taxane, 3) switching to T DM1, 4) clinical trials of targeted agents such as CDK...

Comments

Medical Oncologist at University of Iowa Holden Comprehensive Cancer Center
I agree with answer from Dr. Ma. I would also reco...

Medical Oncologist at Heartland Onc and Hem
Is there any good reason to re biopsy metastatic s...

Answer from: Medical Oncologist at Academic Institution

I agree with both @Cynthia X. Ma and @Praveen Vikas. In addition, level of ER/PR and presence or absence of HER2 heterogeneity, specifically in the repeat biopsy, may further finesse your treatments. For example, if HER2 heterogeneity is present, then TDM1 may be less effective, and first 2 options ...

Comments

Medical Oncologist at Springfield Clinic
Thank you for the discussion. The patient has seco...

Related Questions